

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 81164

Title: Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06097590

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2022-10-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-01 07:04

Reviewer performed review: 2022-11-07 15:29

Review time: 6 Days and 8 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input type="checkbox"/>] Anonymous [<input checked="" type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

I appreciate the opportunity reviewing the manuscript on pancreatic cancer. In this letter to editor, the authors discussed the merits of the combination of gemcitabine and targeted drugs, which may offer additional benefits to patients. The manuscript is generally well-written and the only thing needs clarification is to elaborate the reasons why gemcitabine+ erlotinib had shorter median OS compared to gemcitabine monotherapy in the LAP07 trial (11.9mo vs. 13.6 mo). Is it due to higher adverse effects, such as myelosuppression, or neutropenic fever? Additionally, combination therapy, especially combination with high-cost target drugs, could represent significant financial toxicity to patients who are uncovered or underinsured. Therefore, in real-world studies, choice of combination therapy is usually confounded by multiple factors, introducing selection bias that favor the combination therapy. Authors should mention the discrepancies in real-world practice and RCT findings, and should be cautious in interpreting somehow encouraging results from observational studies.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 81164

Title: Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04423126

Position: Editorial Board

Academic degree: FACS

Professional title: Chief Doctor, Professor

Reviewer's Country/Territory: Germany

Author's Country/Territory: China

Manuscript submission date: 2022-10-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-22 05:52

Reviewer performed review: 2022-11-22 05:57

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

A very good comment regarding the paper of Nishimoto.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 81164

Title: Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03998130

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Senior Lecturer, Surgeon, Surgical Oncologist, Teacher

Reviewer's Country/Territory: Romania

Author's Country/Territory: China

Manuscript submission date: 2022-10-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-26 11:08

Reviewer performed review: 2022-11-26 11:19

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This Letter to the Editor comments on the results of an article published in the World Journal of Gastroenterology by Nishimoto A in 2022. All the comments are pertinent and would interest the journal readers.